专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

US20030232089A1 Ophthalmic formulation with novel gum composition 失效
标题翻译：具有新型口香糖组合物的眼科制剂
公开(公告)号：US20030232089A1
公开(公告)日：2003-12-18
申请号：US10370220
申请日：2003-02-20
发明人： Satish K. Singh , Paramita Bandyopadhyay
IPC分类号： A61K031/736 , A61K031/541 , A61K031/5377 , A61K031/454 , A61K031/496 , A61K031/573 , A61K009/14
CPC分类号： A61K9/0048
摘要： There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising (a) a pharmacologically effective concentration of an active agent and (b) a combination of at least two ophthalmically compatible polymers comprising a novel gum system. In preferred embodiments of the present invention, the compositions increase the retention time of the active agent in the eye, when compared to compositions with other gums or gum systems.
摘要翻译：提供了适合于局部施用于眼睛的药物组合物，所述组合物包含（a）药理学有效浓度的活性剂和（b）至少两种眼科相容性聚合物的组合，其包含新型胶体系统。在本发明的优选实施方案中，当与其它牙龈或牙龈系统的组合物相比时，组合物增加了活性剂在眼中的保留时间。

92. 发明申请

US20030216365A1 Use of mometasone furoate for treating airway passage and lung diseases 失效
公开(公告)号：US20030216365A1
公开(公告)日：2003-11-20
申请号：US10426329
申请日：2003-04-30
发明人： Joel A. Sequeira , Francis M. Cuss , Keith B. Nolop , Imtiaz A. Chaudry , Nagamani Nagabhushan , James E. Patrick , Mitchell Cayen
IPC分类号： A61K031/573 , A61L009/04
CPC分类号： A61K9/008 , A61K9/0043 , A61K9/0075 , A61K31/57 , A61K31/58 , Y10S514/826 , Y10S514/828 , Y10S514/958
摘要： The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

93. 发明申请

US20030212104A1 Treatment of diabetes and diabetic complications with NHE-1 inhibitors 审中-公开
标题翻译：用NHE-1抑制剂治疗糖尿病和糖尿病并发症
公开(公告)号：US20030212104A1
公开(公告)日：2003-11-13
申请号：US10428521
申请日：2003-05-01
申请人： Pfizer Inc.
发明人： W. Ross Tracey , Judith L. Treadway
IPC分类号： A61K038/28 , A61K038/17 , A61K038/22 , A61K031/573 , A61K031/4709 , A61K031/4152 , A61K031/175 , A61K031/155
CPC分类号： A61K45/06 , A61K31/00 , A61K31/4155 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4709 , A61K2300/00
摘要： This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.
摘要翻译：本发明涉及治疗或预防2型糖尿病，糖尿病性神经病，糖尿病性心肌病，白内障，糖尿病性视网膜病，足溃疡，糖尿病性微血管病变，糖尿病性大血管病变，糖尿病性缺血再灌注损伤，糖尿病性心脏缺血再灌注损伤和/或胰岛素抵抗综合征 IRS）在哺乳动物，特别是人类哺乳动物中，通过施用1型氢氧化钠换算器（NHE-1）抑制剂或含有这种抑制剂的药物组合物。本发明还涉及包含NHE-1抑制剂和第二药剂的组合，所述组合可用于治疗2型糖尿病，IRS，糖尿病性神经病，糖尿病性心肌病，白内障，糖尿病性视网膜病，足溃疡，糖尿病性缺血再灌注损伤，糖尿病性心脏病缺血再灌注损伤，糖尿病性微血管病变和/或糖尿病性大血管病变。

94. 发明申请

US20030211157A1 Semi-sol delivery blend for water soluble molecules 审中-公开
标题翻译：水溶性分子的半溶胶输送混合物
公开(公告)号：US20030211157A1
公开(公告)日：2003-11-13
申请号：US10306657
申请日：2002-11-27
发明人： David Lew Simon
IPC分类号： A61K031/573 , A61K031/485 , A61K009/14
CPC分类号： A61K31/485 , A61K9/0024 , A61K2300/00
摘要： The present invention relates to novel methods and compositions for administration of water-soluble small molecules for the treatment of opioid addiction, alcoholism and HIV infection, especially where the water-soluble small molecules are pentacyclic and structurally similar to nalmefene, buprenorphine, 6-beta-naltrexol and nalbuphine.
摘要翻译：本发明涉及用于治疗阿片样物质成瘾，酒精中毒和HIV感染的水溶性小分子的新方法和组合物，特别是其中水溶性小分子是五环和结构上类似于萘美芬，丁丙诺啡，6-β 纳曲酮和纳布啡。

95. 发明申请

US20030207854A1 Antiprogestins with partial agonist activity 审中-公开
标题翻译：具有部分激动剂活性的抗孕激素
公开(公告)号：US20030207854A1
公开(公告)日：2003-11-06
申请号：US10239548
申请日：2002-09-23
发明人： S. Stoney Simons, Jr.
IPC分类号： A61K031/573
CPC分类号： A61K31/573
摘要： The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or prevention. The methods include administering an effective amount of a C-17-derivatized dexamethasone antiprogestin to the cell or the subject. The invention also provides methods of screening substances for progestin or antiprogestin activity, and methods of detecting progestins, progestin agonists, or antiprogestins in a sample, using the C-17-derivatized dexamethasone antiprogestins of the invention.
摘要翻译：本发明的特征在于抑制需要这种抑制的细胞或受试者中孕激素活性的方法，以及在需要这种治疗或预防的对象中治疗或预防孕激素依赖性病症的方法。所述方法包括向细胞或受试者施用有效量的C-17-衍生的地塞米松抗孕激素。本发明还提供了使用本发明的C-17衍生化的地塞米松抗孕激素来筛选孕激素或抗孕激素活性的物质的方法以及在样品中检测孕激素，孕激素激动剂或抗孕激素的方法。

96. 发明申请

US20030194446A1 Zinc oxide compositions for dermatheraputics 审中-公开
标题翻译：用于皮肤科的氧化锌组合物
公开(公告)号：US20030194446A1
公开(公告)日：2003-10-16
申请号：US10119304
申请日：2002-04-10
发明人： Lindy K. Akes , Michael E. Cournoyer
IPC分类号： A61K031/7048 , A61K031/704 , A61K031/573 , A61K031/496 , A61K033/22 , A61K031/47 , A61K031/4196
CPC分类号： A61K31/704 , A61K31/4196 , A61K31/47 , A61K31/496 , A61K31/573 , A61K31/7048 , A61K33/30 , A61K2300/00
摘要： 20% Zinc oxide formulations including up to 5% of at least one pharmacologically active agent and associated topical methods for improved therapeutic treatment of adverse atopic dermatological conditions.
摘要翻译： 20％氧化锌制剂，包括至多5％的至少一种药理学活性剂和相关的局部方法，用于改善对不利特应性皮肤病学条件的治疗性治疗。

97. 发明申请

US20030171344A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester 有权
标题翻译：包含丙二醇和异丙基链烷酸酯的抗病毒制剂
公开(公告)号：US20030171344A1
公开(公告)日：2003-09-11
申请号：US10334487
申请日：2002-12-30
申请人： Medivir AB
发明人： Gunilla Lekare
IPC分类号： A61K031/7076 , A61K031/7072 , A61K031/573 , A61K031/522 , A61K031/513
CPC分类号： A61K9/0014 , A61K47/14 , A61K47/44
摘要： A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to about 25 weight % propylene glycol and about 10 to about 25 weight percent isopropyl C12-C22 alkanoic ester. The compositions have utility in the treatment or prophylaxis of herpesvirus infections and exhibit superior antiviral and therapeutic efficacy and an improved shelf life.
摘要翻译：一种在药物载体中包含抗炎糖皮质激素和核苷类似物抗病毒剂的局部组合物，其特征在于载体包含约15至约25重量％的丙二醇和约10至约25重量％的异丙基C12-C22链烷酸酯。该组合物可用于治疗或预防疱疹病毒感染并表现出优异的抗病毒和治疗功效以及改善的保质期。

98. 发明申请

US20030158163A1 Organic compounds 失效
标题翻译：有机化合物
公开(公告)号：US20030158163A1
公开(公告)日：2003-08-21
申请号：US10312021
申请日：2002-12-20
发明人： Bernard Cuenoud , David Beattie , Thomas Hugo Keller , Gaynor Elizabeth Pilgrim , David Andrew Sandham , Simon James Watson
IPC分类号： A61K031/58 , A61K031/573 , C07J043/00 , C07J017/00 , C07J007/00
CPC分类号： C07J41/0038 , C07J3/005 , C07J17/00 , C07J33/002 , C07J41/0094 , C07J43/003 , C07J71/0015
摘要： Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
摘要翻译：式（I）化合物，其中R是环系中具有3至15个原子的一价环状有机基团，可用作药物。

99. 发明申请

US20030148975A1 Method of achieving persistent transgene expression 审中-公开
标题翻译：实现持续转基因表达的方法
公开(公告)号：US20030148975A1
公开(公告)日：2003-08-07
申请号：US10169323
申请日：2002-10-23
发明人： David Ennist , Patrick Lu , Mervat Mina
IPC分类号： A61K048/00 , A61K031/715 , A61K031/573
CPC分类号： C12N15/87 , A61K48/0075 , A61K48/0083
摘要： Non-inflammatory vector compositions are provided that are suitable for repeated transgene delivery and that result in persistent transgene expression. The compositions are non-inflammatory, the present compositions are suitable for readministration and do not induce expression-limiting immune or inflammatory responses. Thus, these compositions are useful in methods of repeated administration to achieve persistent transgene expression, and are especially suited to treating genetic, acquired and inflammation-associated conditions.
摘要翻译：提供非炎症载体组合物，其适用于重复的转基因递送，并导致持续的转基因表达。组合物是非炎性的，本发明的组合物适用于再次给药并且不诱导表达限制性免疫或炎症反应。因此，这些组合物可用于重复施用以实现持续转基因表达的方法，并且特别适合于治疗遗传，获得性和炎症相关病症。

100. 发明申请

US20030143246A1 Ganoderma lucidum spores for treatment of autoimmune diseases 失效
标题翻译：灵芝孢子用于治疗自身免疫性疾病
公开(公告)号：US20030143246A1
公开(公告)日：2003-07-31
申请号：US10234103
申请日：2002-09-05
发明人： Chee-Keung Chung , Siu Kan Tong
IPC分类号： A61K035/84 , A61K031/573
CPC分类号： A61K36/074 , C12N1/14 , Y10S514/885
摘要： The present invention provides a method for treating a mammal with immunological disorders, particularly autoimmune disease, and most preferably systemic lupus erythematosus (SLE). The method includes oral administration of germination activated Ganoderma lucidum spores (nullGLSsnull) to the mammal. Additionally, a corticosteroid, such as prednisolone, can be co-administered with the GLSs to the mammal to achieve synergistic effect of treatment.
摘要翻译：本发明提供了一种治疗具有免疫学障碍，特别是自身免疫疾病，最优选系统性红斑狼疮（SLE）的哺乳动物的方法。该方法包括向哺乳动物口服施用发芽活化的灵芝孢子（“GLSs”）。此外，皮质类固醇如泼尼松龙可与哺乳动物的GLS共同施用以达到治疗的协同效应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式